Abstract:Background: Lipopolysaccharide(LPS) inserts into the hydrophobic binding pocket of the myeloid differentiation protein 2(MD-2) that bound to toll-like receptor 4(TLR4). TLR4 antagonists have been designed based on the structure of lipid A, the innermost regions of LPS. However, these antagonists have poor bioavailability and may be toxic. Furthermore, the presence of lipid A moiety is not necessary for driving TLR4 activation. Therefore, compound directly binds to TLR4 is a better strategy to inhibit TLR4 activity. Methods: Biophysical techniques were used to examine the direct binding between baicalein and TLR4. With colorectal cancer(CRC) as models, coupled with drug-target-disease network, protein-protein interaction network and functional studies, the effect and the associated underlying mechanism of action upon the binding baicalein to TLR4 were examined. Findings: We evidently show a direct physical binding of baicalein to TLR4 in molecular docking, surface plasmon resonance biosensor analysis and bio-layer interferometry analysis. With CRC cells as model, we demonstrate the binding of baicalein to TLR4 with cellular thermal shift assay; which interrupts the binding of LPS to TLR4-MD-2 in the cells. Baicalein inhibits TLR4 activity, reduces CRC cell viability and migration in TLR4-dependent manner. Drug–targets–disease network and protein-protein interaction network highlight hypoxia inducible factor(HIF-1α) and vascular endothelial growth factor(VEGF) as downstream of TLR4, which are further validated in cell models. Involvement of TLR4/HIF-1α/VEGF axis in the anti-CRC and anti-angiogenic effect of baicalein is demonstrated in CRC-bearing mice and chick-chorioallantoic-membrane assay, respectively. Our study provides evidence to support the translation of baicalein into TLR4-targeting therapeutics. Funding Information: This work was partially supported by Research Grant Council of HKSAR HKBU-22103017-ECS, Innovation & Technology Commission #PRP/015/19FX, National Natural Science Foundation of China #SCM-2016-NSFC-003 and Natural Science Foundation of Guangdong Province #2018A0303130122 to HYK; the National Natural Science Foundation of China (82074019 and 81703705), Characteristic innovation projects of universities in Guangdong Province (2020KTSCX030), the Opening Project of Zhejiang Provincial Preponderant and Characteristic Subject of Key University (Traditional Chinese Pharmacology), Zhejiang Chinese Medical University (ZYAOX2018010) to ST. Declaration of Interests: The authors declare that they have no conflict of interest. Ethics Approval Statement: Animal experiments were approved by the Guangzhou University of Chinese Medicine Animal Care and Use Committee (Guangzhou, China), and conducted according to the ethical standards and national guidelines.

[Effect of Baicalin on Pattern Recognition Receptor TLR2/4-NOD2 and Its Significance of Druggability].

Retracted: Baicalin Relieves TNF‐α‐evoked Injury in Human Aortic Endothelial Cells by Up‐regulation of Mir‐145

Comprehensive Study of Baicalin Down-Regulating Nod2 Receptor Expression of Neurons with Oxygen-Glucose Deprivation in Vitro and Cerebral Ischemia-Reperfusion in Vivo

Study on Inflammatory Mechanism between Lung and Brain by the Action of Baicalin on TLRs-NOD2 Signaling

Identification of potential regulating effect of baicalin on NFκB/CCL2/CCR2 signaling pathway in rats with cerebral ischemia by antibody-based array and bioinformatics analysis

Role of Baicalin in Regulating Toll-like Receptor 2/4 after Ischemic Neuronal Injury.

Baicalin Mitigates the Neuroinflammation through the TLR4/MyD88/NF-κB and MAPK Pathways in LPS-Stimulated BV-2 Microglia

Baicalin inhibits inflammation of lipopolysaccharide-induced acute lung injury <i>via</i> toll like receptor-4/myeloid differentiation primary response 88/nuclear factor-kappa B signaling pathway

Baicalin Attenuates Toll-like Receptor 4 Expression in Lipopolysaccharide-Treated Macrophage Cells

Identification of Baicalin As an Immunoregulatory Compound by Controlling TH17 Cell Differentiation

Baicalin Attenuates Proinflammatory Cytokine Production In Oxygen-Glucose Deprived Challenged Rat Microglial Cells By Inhibiting Tlr4 Signaling Pathway

The Protective Role of Baicalin in the Regulation of NLRP3 Inflammasome in Different Diseases

Baicalein ameliorates TNBS-induced colitis by suppressing TLR4/MyD88 signaling cascade and NLRP3 inflammasome activation in mice

Baicalin Targets HSP70/90 to Regulate PKR/PI3K/AKT/eNOS Signaling Pathways

The Pharmacological Efficacy of Baicalin in Inflammatory Diseases

Therapeutic potentials of baicalin and its aglycone, baicalein against inflammatory disorders

Therapeutic effect of baicalin on inflammatory bowel disease: A review

Anti-inflammatory and immunomodulatory effects of baicalin in cerebrovascular and neurological disorders

Baicalein Binds to TLR4, Inhibits Colorectal Cancer Growth and Metastasis via the TLR4/HIF/VEGF Axis

Baicalin and the liver-gut system: Pharmacological bases explaining its therapeutic effects

Mechanisms in mediating the anti-inflammatory effects of baicalin and baicalein in human leukocytes